x

Posted 21 July, 2022

Salona Global Medical Device Corp appointed Luke Faulstick as new CEO

OTC:LNDZF appointed new Chief Executive Officer Luke Faulstick in a 8-K filed on 21 July, 2022.


  On July 14, 2022, Luke Faulstick, age 59, was appointed as Chief Executive Officer of the Company effective as of July 18, 2022.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Salona Global Medical Device Corp
Health Care/Life Sciences • Medical Equipment/Supplies
Evome Medical Technologies, Inc. engages in the provision of financial and consultancy services to the mental health and addiction industry. It operates through the Medical Billing and Financial Services segments. The Medical Billing segment focuses on its customers in United States. The Financial Services segment offers asset based financial services to healthcare providers in the United States. The company was founded by Robert Munro on September 17, 2013 and is headquartered in Shirley, NY.
Market Cap
$5.84M
View Company Details
Salona Global Medical Device Corp by TradingView
Relevant filing section
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 14, 2022, Luke Faulstick, age 59, was appointed as Chief Executive Officer of the Company effective as of July 18, 2022. Prior to his appointment, Mr. Faulstick served as the Chief Operating and Integration‎ Officer ‎of the Company since 2021. Since 2012 has served as the President of the Company's wholly owned subsidiary and manufacturing unit, South Dakota Partners, Inc. ("SDP") acquired in 2021, where he led organic growth and continuing acquisitions to increase revenues. In his executive career, Mr. Faulstick has held leadership positions at DJO Global Inc. (EVP/COO); Tyco Healthcare (General Manager); Graphic Controls (General Manager); Mitsubishi Consumer Electronics (Plant Manager); and Eastman Kodak. He previously served on the boards of Alphatec Spine (NASDAQ: ATEC) and Orthofix (NASDAQ: OFIX). Mr. Faulstick studied at both Michigan State University and Rochester Institute of Technology.

Mr. Faulstick has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K promulgated under the Securities Exchange Act of 1934, as amended, nor are any such transactions currently proposed.

A copy of the news release issued by the Company on July 14, 2022 announcing Mr. Faulstick's appointment to as Chief Executive Officer, as well as the Company's financial results for the quarter ended May 31, 2022, was attached to the Company's current report on Form 8-K filed on July 14, 2022.